Trials / Completed
CompletedNCT03180437
Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Fuda Cancer Hospital, Guangzhou · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
In this study, effects of γδT cells on human Pancreatic Cancer in combination with tumor reducing surgery, for example IRE going to be investigated.
Detailed description
Pancreatic tumor will be removed using tumor reducing surgery such as IRE. PBMC of the healthy donor will be separated from peripheral blood. After making them potential cancer killer γδ T Cell, they will be infused to the patients as an immunotherapy treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | IRE surgery | IRE surgery will be used in local tumor |
| BIOLOGICAL | IRE plus γδ T cells | Combination IRE surgery and γδ T cell will be used in Pancreatic Cancer |
Timeline
- Start date
- 2017-06-15
- Primary completion
- 2018-06-15
- Completion
- 2019-06-15
- First posted
- 2017-06-08
- Last updated
- 2020-11-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03180437. Inclusion in this directory is not an endorsement.